Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 23Observational 2Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Recurrence 2Leukemia, Myeloid, Acute 2

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × gilteritinib × Clear all
NCT06734585 2025-09-12

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Astellas Pharma Inc

Completed
114 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04691648 2025-05-31

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Astellas Pharma Inc

Completed
33 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡